Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from Analysts
MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the sixteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating,
NASDAQ:PTGX